Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nedocromil · 1 trial · 1 indication
Maximal percent drop in FEV1 at 20 minutes post allergen challenge
Fold change over baseline of plasma 9P at 5 minutes post-allergen challenge
Fold change over baseline of plasma 9P at 20 minutes post-allergen challenge
| Arm | Type | Description |
|---|---|---|
| Placebo | EXPERIMENTAL | Placebo |
| Montelukast | EXPERIMENTAL | Montelukast |
| Nedocromil | EXPERIMENTAL | Nedocromil |
| Mometasone | EXPERIMENTAL | Mometasone |
| Name | Type | Description |
|---|---|---|
| Nedocromil | DRUG | Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge |
| Comparator: Montelukast | DRUG | Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge |
| Comparator: Mometasone | DRUG | Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge |
| Placebo | DRUG | Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet |
Inclusion Criteria: * History of mild to moderate Asthma * In good general health (except for asthma) * Stable and free of respiratory infection * Nonsmoker * Females highly unlikely to conceive (surgically sterilized, postmenopausal, or agrees to use 2 acceptable methods of birth control) Exclusi...
Nedocromil is a small molecule being investigated for the treatment of asthma. It is currently in Phase 1 clinical development. The drug is being studied for its effects on the early airway response to allergen in asthmatic patients.
Nedocromil is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with asthma.
Nedocromil is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for its potential use in treating asthma.
Nedocromil has one completed clinical trial registered as NCT01061333, titled "Early Airway Response to Allergen in Asthmatics (MK-0000-176)." This Phase 1 study enrolled 16 participants with asthma and was a randomized, double-blind, controlled trial.
Nedocromil is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for asthma. The drug has completed one clinical trial, but it remains under investigation and has not received regulatory approval.